Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.
Some insights
Peptone's investment in Bellinzona follows a 40 million dollar funding round completed in April 2022. The company plans to create up to 20 new jobs in their new Swiss hub by the end of 2023 and around 30 highly specialised qualified employees will be working in interdisciplinary teams in Bellinzona.